Drug intelligence / Profile preview

ASFV Toxoid Orf Vaccine

Development stage: Preclinical
Lead developer: Kermode Biotechnologies
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Intranasal, Oral, Parenteral

Overview

ASFV Toxoid Orf Vaccine is a veterinary vaccine candidate developed by Kermode (formerly Porcine Therapeutics) for the prevention of African Swine Fever Virus (ASFV) infection in swine. The vaccine utilizes a proprietary Orf virus (ORFV) vector-based delivery system to present multiple ASFV antigens (Open Reading Frames) to the host immune system. This 'toxoid-like' approach is designed to induce broad and protective immune responses against the complex ASFV pathogen. As of 2024, the program is in the early stages of development, with research focused on characterizing immune responses in porcine models.

Other names: ASFV ORF-based toxoid vaccine

Targets

ASFV (African swine fever virus)

Beyond the preview

Go deeper on ASFV Toxoid Orf Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASFV Toxoid Orf Vaccine.

Explore the full profile